CXCR4-Targeted Nanocarriers for Triple Negative Breast Cancers

Asish C. Misra; Kathryn E. Luker; Hakan Durmaz; Gary D. Luker; Joerg Lahann

doi:10.1021/acs.biomac.5b00653

CXCR4-Targeted Nanocarriers for Triple Negative Breast Cancers

Asish C. Misra
, Kathryn E. Luker
, Hakan Durmaz
, Gary D. Luker
, Joerg Lahann^*

^*Corresponding author for this work

University of Michigan, Ann Arbor
Karlsruhe Institute of Technology

Research output: Contribution to journal › Article › peer-review

41 Citations (Scopus)

Abstract

CXCR4 is a cell membrane receptor that is overexpressed in triple-negative breast cancers and implicated in growth and metastasis of this disease. Using electrohydrodynamic cojetting, we prepared multicompartmental drug delivery carriers for CXCR4 targeting. The particles are comprised of a novel poly(lactide-co-glycolide) derivative that allows for straightforward immobilization of 1,1′-[1,4-phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] (Plerixafor), a small molecule with affinity for CXCR4. Targeted nanocarriers are selectively taken up by CXCR4-expressing cells and effectively block CXCR4 signaling. This study suggests that CXCR4 may be an effective target for nanocarrier-based therapies. (Figure Presented).

Original language	English
Pages (from-to)	2412-2417
Number of pages	6
Journal	Biomacromolecules
Volume	16
Issue number	8
DOIs	https://doi.org/10.1021/acs.biomac.5b00653
Publication status	Published - 10 Aug 2015
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2015 American Chemical Society.

Funding

Funders	Funder number
Army Research Office	W911NF-10-1-0518
U.S. Department of Defense	W81XWH-11-1-0111
National Cancer Institute	R01CA170198

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1021/acs.biomac.5b00653

Cite this

@article{0393ef9e6e3640a58a47e3262983d0cd,

title = "CXCR4-Targeted Nanocarriers for Triple Negative Breast Cancers",

abstract = "CXCR4 is a cell membrane receptor that is overexpressed in triple-negative breast cancers and implicated in growth and metastasis of this disease. Using electrohydrodynamic cojetting, we prepared multicompartmental drug delivery carriers for CXCR4 targeting. The particles are comprised of a novel poly(lactide-co-glycolide) derivative that allows for straightforward immobilization of 1,1′-[1,4-phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] (Plerixafor), a small molecule with affinity for CXCR4. Targeted nanocarriers are selectively taken up by CXCR4-expressing cells and effectively block CXCR4 signaling. This study suggests that CXCR4 may be an effective target for nanocarrier-based therapies. (Figure Presented).",

author = "Misra, \{Asish C.\} and Luker, \{Kathryn E.\} and Hakan Durmaz and Luker, \{Gary D.\} and Joerg Lahann",

note = "Publisher Copyright: {\textcopyright} 2015 American Chemical Society.",

year = "2015",

month = aug,

day = "10",

doi = "10.1021/acs.biomac.5b00653",

language = "English",

volume = "16",

pages = "2412--2417",

journal = "Biomacromolecules",

issn = "1525-7797",

publisher = "American Chemical Society",

number = "8",

}

TY - JOUR

T1 - CXCR4-Targeted Nanocarriers for Triple Negative Breast Cancers

AU - Misra, Asish C.

AU - Luker, Kathryn E.

AU - Durmaz, Hakan

AU - Luker, Gary D.

AU - Lahann, Joerg

PY - 2015/8/10

Y1 - 2015/8/10

N2 - CXCR4 is a cell membrane receptor that is overexpressed in triple-negative breast cancers and implicated in growth and metastasis of this disease. Using electrohydrodynamic cojetting, we prepared multicompartmental drug delivery carriers for CXCR4 targeting. The particles are comprised of a novel poly(lactide-co-glycolide) derivative that allows for straightforward immobilization of 1,1′-[1,4-phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] (Plerixafor), a small molecule with affinity for CXCR4. Targeted nanocarriers are selectively taken up by CXCR4-expressing cells and effectively block CXCR4 signaling. This study suggests that CXCR4 may be an effective target for nanocarrier-based therapies. (Figure Presented).

AB - CXCR4 is a cell membrane receptor that is overexpressed in triple-negative breast cancers and implicated in growth and metastasis of this disease. Using electrohydrodynamic cojetting, we prepared multicompartmental drug delivery carriers for CXCR4 targeting. The particles are comprised of a novel poly(lactide-co-glycolide) derivative that allows for straightforward immobilization of 1,1′-[1,4-phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] (Plerixafor), a small molecule with affinity for CXCR4. Targeted nanocarriers are selectively taken up by CXCR4-expressing cells and effectively block CXCR4 signaling. This study suggests that CXCR4 may be an effective target for nanocarrier-based therapies. (Figure Presented).

UR - https://www.scopus.com/pages/publications/84938919538

U2 - 10.1021/acs.biomac.5b00653

DO - 10.1021/acs.biomac.5b00653

M3 - Article

C2 - 26154069

AN - SCOPUS:84938919538

SN - 1525-7797

VL - 16

SP - 2412

EP - 2417

JO - Biomacromolecules

JF - Biomacromolecules

IS - 8

ER -

CXCR4-Targeted Nanocarriers for Triple Negative Breast Cancers

Abstract

Bibliographical note

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this